In this video, an expert panel discusses progress in biomedical HIV prevention technologies for women, as well as treatment as prevention.
The panel includes:
- Carl Dieffenbach, Ph.D., Director of the Division of AIDS, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, M.D.
- Nelly Mugo, M.D., M.P.H., Research Scientist at the University of Washington and the University of Nairobi/Kenyatta National Hospital, and East African Director of the Partners in Prevention HSV/HIV Transmission Study
- Julio Montaner, M.D., Director of the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
Hosting this panel is Yasmin Halima, Executive Director of the Global Campaign for Microbicides at PATH.
The video above has been cross-posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's blog to watch more video interviews from the conference.
Comment by: michael
Wed., Mar. 21, 2012 at 2:27 pm EDT
no surprise here. it is frustrating that these studies seem to be several steps behind of the patients. many hiv patients have brought this up to their doctors but as always, they often dismiss it as it will pass because there is no "written study" on it happening.....which is idiotic because here are your patients saying it is happening. this medical industry lacks innovation and free thinkers like the german doctor who cured (yes cured) the first hiv infected man....and wouldn't you know it, he's not even an HIV specialist.......the majority of doctors and specialists are just rank and file drones robosigning prescriptions for the drug companies. no real thinkers to think outside the box to cure, not treat, HIV and other diseases and disorders. DON'T TREAT US, CURE US!
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy